102 results
8-K
EX-99.1
ANNX
Annexon Inc
13 May 24
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
4:05pm
are designed to provide meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic diseases. With proof-of concept data in Guillain-Barré … -of-concept data for ANX1502; continued development of ANX007 and ANX1502; anticipated cash runway into mid-2026; the potential benefits from
8-K
EX-99.1
ANNX
Annexon Inc
7 May 24
Other Events
4:05pm
are designed to provide meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic diseases. With proof-of concept data in Guillain-Barré … dependent preservation of vision loss in the broad patient population; the potential benefits from treatment with anti-C1q therapy; and Annexon’ s
424B5
ANNX
Annexon Inc
5 Apr 24
Prospectus supplement for primary offering
4:07pm
persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our
8-K
EX-99.1
sis252kk
26 Mar 24
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
4:05pm
8-K
EX-99.1
xbal6es1 5cwc7
4 Mar 24
Regulation FD Disclosure
5:25pm
8-K
EX-99.1
b1uryu62wgsxoscivc0n
8 Jan 24
Regulation FD Disclosure
4:09pm
8-K
EX-99.1
zu0932jemyfb7 3d
21 Dec 23
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
4:09pm
8-K
EX-1.1
09axf6j
21 Dec 23
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
4:09pm
424B5
iwkt uku57eyfy8ahwqf
21 Dec 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
52zjb
20 Dec 23
Regulation FD Disclosure
5:17pm